Humana (NYSE:HUM) Given New $602.00 Price Target at Wells Fargo & Company

Humana (NYSE:HUM) had its price target upped by equities research analysts at Wells Fargo & Company from $502.00 to $602.00 in a report issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the insurance provider’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 34.88% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Leerink Partners raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price on the stock in a report on Thursday, July 30th. HSBC downgraded shares of Humana to a “hold” rating in a research report on Thursday, July 30th. TD Cowen lifted their price target on shares of Humana from $370.00 to $430.00 and gave the company a “hold” rating in a report on Wednesday. Truist Financial boosted their price objective on shares of Humana from $415.00 to $475.00 and gave the company a “hold” rating in a research report on Monday, October 12th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $420.00 price objective on shares of Humana in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $476.52.

Humana Stock Performance

HUM stock opened at $446.33 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61. The firm has a market cap of $53.60 billion, a P/E ratio of 43.42, a P/E/G ratio of 2.30 and a beta of 0.65. Humana has a 12-month low of $163.11 and a 12-month high of $456.50. The stock’s 50 day simple moving average is $406.79 and its 200 day simple moving average is $314.80.

Humana (NYSE:HUM) last announced its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.30. The firm had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period last year, the business posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities research analysts predict that Humana will post 9.56 EPS for the current year.

Hedge Funds Weigh In On Humana

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Humana in the 2nd quarter worth about $4,138,160,000. Pzena Investment Management LLC acquired a new position in Humana during the 2nd quarter valued at about $1,749,014,000. Assenagon Asset Management S.A. boosted its stake in Humana by 20,126.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after purchasing an additional 1,249,272 shares during the period. Legal & General Group Plc bought a new position in Humana in the 2nd quarter worth about $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC bought a new position in Humana in the 2nd quarter worth about $314,922,000. Institutional investors own 92.38% of the company’s stock.

Humana News Roundup

Here’s some of the latest news about HUM:

• Positive Sentiment: Zacks Research upgraded Humana to Strong Buy, citing improving earnings prospects. A separate report also noted a fair-value increase following the company’s star-rating update and third-quarter results. Zacks Strong Buy upgrade Fair-value assessment
• Positive Sentiment: JPMorgan raised its price target to $484 from $393 while maintaining a Neutral rating, and a separate report said the bank sees Humana’s shares as positioned to rise. The higher target adds to favorable post-earnings analyst attention. JPMorgan view on Humana shares
• Negative Sentiment: TD Cowen raised its target to $430 from $370 but kept a Hold rating; that target is below the $446.33 reference price, offering a more cautious counterpoint to recent bullish calls. Analyst and company updates

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.